Why the study?
Does the serum concentration of pro-inflammatory cytokines (TNF-α and IL-6) predict death or heart failure hospitalization in patients with heart failure and comorbidities?
Does the serum concentration of pro-inflammatory cytokines (TNF-α and IL-6) predict death or heart failure hospitalization in patients with heart failure and comorbidities?
Elevated serum IL-6, but not TNF-α, is an independent predictor of death and worsening heart failure in patients with HF, particularly those with comorbid diabetes and chronic kidney disease.
Elevated TNFα/IL-6 may flag worse prognosis in HF with DM/CKD; leaves open incremental value beyond routine markers.
Background: Heart failure (HF) often coincides with diabetes type 2 (DM) and chronic kidney disease (CKD). In the course of these disorders markers of inflammation such as tumour necrosis factor α (TNFα) and interleukin 6 (IL-6) are elevated. Inflammatory cytokines are markers of bad prognosis. The aim of the study was to assess the severity of inflammation in the course of HF, DM and CKD. We also evaluated the prognostic value TNFα and IL-6 serum concentration. Methods: 129 patients with HF were enrolled. 50% of the patients had DM, 50% CKD of the stage 3 and 30% patients had both diseases. The serum concentration of TNF-α and IL-6 were assessed by ELISA method. Endpoints are death and hospitalization due to worsening of HF during the 12 months of follow-up. Results: The lowest serum concentration of IL-6 was in patient with only HF, the highest in patients with HF and DM The highest serum concentration of TNF-α was found in patients with HF, DM and CKD and the lowest in patients with only HF. IL-6 was the predictor of the composite end point in multivariate analysis. TNF-α was not found to be a predictive factor. Conclusions: Inflammatory condition presented by concentration of pro-inflammatory cytokines seems to be the lowest in patients with heart failure only and increases when comorbidities appear. Only IL6 has the prognostic value. Elevated concentrations of IL-6 increases the risk of the composite end point.
No takes yet. Share an insight, caveat, or question.
Dyrla et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: